OTCMKTS:CYYNF Cynata Therapeutics (CYYNF) Stock Price, News & Analysis $0.15 +0.01 (+8.70%) As of 05/5/2025 09:31 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartHeadlinesShort InterestBuy This Stock About Cynata Therapeutics Stock (OTCMKTS:CYYNF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cynata Therapeutics alerts:Sign Up Key Stats Today's Range$0.15▼$0.1550-Day Range$0.14▼$0.1552-Week Range$0.14▼$0.15Volume5,000 shsAverage Volume125 shsMarket Capitalization$26.94 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewCynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds. In addition, the company develops products for the treatment of asthma, heart attack, coronary artery disease, brain cancer, sepsis, acute respiratory distress syndrome, critical limb ischemia, idiopathic pulmonary fibrosis, and renal transplantation. Cynata Therapeutics Limited has a strategic partnership with Fujifilm to provide clinical and commercial manufacturing services for, and supply of, Cynata's Cymerus therapeutic mesenchymal stem cell products. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.Read More… Receive CYYNF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cynata Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CYYNF Stock News HeadlinesCynata Therapeutics Hosts Investor Webinar to Highlight Clinical AdvancementsMay 4 at 7:58 PM | tipranks.comCynata Therapeutics Advances Clinical Trials with Promising DevelopmentsApril 23, 2025 | tipranks.comElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of collapse and built two of the most valuable companies in history. Now, he's sounding the alarm about America's $36 trillion debt time bomb that could destroy the fabric of our society.As head of the Department of Government Efficiency (DOGE) under President Trump, Musk is exposing just how bad things are...May 6, 2025 | American Hartford Gold (Ad)Cynata Therapeutics Joins National Regenerative Medicine InitiativeApril 23, 2025 | tipranks.comCynata Therapeutics Updates Director’s Interest NoticeApril 1, 2025 | tipranks.comCynata Therapeutics Showcases at Advanced Therapies Congress 2025March 17, 2025 | tipranks.comCynata Therapeutics Engages Investors at Euroz Hartleys ConferenceMarch 11, 2025 | tipranks.comCynata Therapeutics Reports Financial Results for Half-Year Ending December 2024February 27, 2025 | tipranks.comSee More Headlines CYYNF Stock Analysis - Frequently Asked Questions How have CYYNF shares performed this year? Cynata Therapeutics' stock was trading at $0.19 at the beginning of the year. Since then, CYYNF stock has decreased by 21.1% and is now trading at $0.15. View the best growth stocks for 2025 here. How do I buy shares of Cynata Therapeutics? Shares of CYYNF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today5/06/2025Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Sanitary paper products Sub-IndustryN/A Current SymbolOTCMKTS:CYYNF CIKN/A Webwww.cynata.com Phone61 3 9824 5254FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares179,632,000Free FloatN/AMarket Cap$26.94 million OptionableNot Optionable Beta0.53 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (OTCMKTS:CYYNF) was last updated on 5/6/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Being Erased – Save It Before It’s Gone ForeverWhat If America's Gold Reserves Are a Lie? For decades, the U.S. government has claimed to have thousands o...Hamilton Gold Group | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredAll Signs Point To Collapse - 401(k)s/IRAs /Are DoomedRetiring? Not so Fast..Hold Onto Your Bootstraps For A Long Road AheadAmerican Hartford Gold | SponsoredTrump’s Bitcoin Reserve is No Accident…Crypto policy is changing fast… Smart investors are positioning themselves to benefit. And it's all happeni...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cynata Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Cynata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.